Nov 09, 2022 / 08:50PM GMT
Matthew Weston - Crédit Suisse AG - Research Division - MD and Co-Head of European Pharmaceutical Equity Research
Good afternoon, everyone. The company is represented by Peter Griffith, CFO and Dave Reese, EVP of R&D. My name is Matthew Weston. For those of you who don't know me, I cover European therapeutics for Credit Suisse.
Gentlemen, thank you so much for joining us. And I think you want to make a few opening comments before we jump in with the discussion.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
Great. Matt, thank you, and thank you, Credit Suisse. We're delighted to be here.
So I'd just like to give you a couple of thoughts. The third quarter was another quarter of solid execution for Amgen despite the macro headwinds that we're all facing out there that reflected volume-driven growth. In the inflamm portfolio, our TEZSPIRE launch continues to be strong and moving ahead for patients with severe asthma. We closed the acquisition of ChemoCentryx recently. Great deployment of our shareholders'
Amgen Inc at Credit Suisse Healthcare Conference Transcript
Nov 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers